Welcome to GBIOLOGICS Inc.
GBIO is a biotechnology company to develop novel protein therapeutics with Open Innovation strategy, reaching out to the global markets. The recombinant protein called stable Galectin-9 (sGal-9) is the main platform technology that was patented in the U.S. and Japan. GBIO’s long-term goal is to enter the U.S. market with new biological products based on sGal-9 and spread seeds of hope for healthy living of human beings in the long run.
The flagship pipeline, GB910, is for the treatment of RA (Rheumatoid Arthritis) with dual action effects on the osteoporosis complication of RA patients, aiming the best-in-class among conventional inflammation therapies, chemical and biological DMARDs (disease modifying antirheumatic drugs). The second one, GB920, is targeting KRAS-mutant cancers (pancreatic and colorectal) with powerful cancer cell apoptosis mechanism as the first-in-class product. The third one, GB930, is an innovative best-in-class DABA (dual action bone agent) drug for osteoporosis (OP) patients by inducing osteoblasts and suppressing osteoclasts at the same time.
GBIO’s Open Innovation network has been extended over Korea to China, Japan, and Northern Europe countries, which is a big step up for GBIO to be a global biopharmaceutical company.
GBIO will grow step-by-step into a top-tier company in the international markets and continue to commercialize the above 3 new drug pipelines on time with the GBIO Way - Re-Search, Connect & Develop, and Speed-to-Market for the success of GBIO and its clients.